{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus+Infections&page=5",
    "query": {
      "condition": "Adenovirus Infections",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 201,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus+Infections&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus+Infections&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T00:42:53.805Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04364178",
      "title": "Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus"
      ],
      "interventions": [
        {
          "name": "Adenovirus Specific T- Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytomegalovirus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EBV Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jessie L. Alexander, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2020-08-12",
      "completion_date": "2023-11-11",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04364178"
    },
    {
      "nct_id": "NCT05183490",
      "title": "R-MVST Cells for Treatment of Viral Infections",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections",
        "Cytomegalovirus Infections",
        "Adenovirus",
        "BK Virus Infection"
      ],
      "interventions": [
        {
          "name": "Rapidly generated virus specific T (R-MVST) cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2022-05-03",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05183490"
    },
    {
      "nct_id": "NCT01174095",
      "title": "Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease",
        "Ischemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 31,
      "start_date": "2009-05",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 2,
      "location_summary": "New York, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01174095"
    },
    {
      "nct_id": "NCT00082641",
      "title": "Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "autologous dendritic cell-adenovirus p53 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 120 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2004-01-01",
      "completion_date": "2018-01-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082641"
    },
    {
      "nct_id": "NCT02231866",
      "title": "Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Immune Responses to Vaccine"
      ],
      "interventions": [
        {
          "name": "VRC-EBOADC069-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-EBOADC076-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 143,
      "start_date": "2014-08-27",
      "completion_date": "2017-04-05",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231866"
    },
    {
      "nct_id": "NCT00618605",
      "title": "Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ad26.ENVA.01 HIV-1 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-02",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00618605"
    },
    {
      "nct_id": "NCT00486408",
      "title": "Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MRKAd5 HIV-1 gag/pol/nef",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486408"
    },
    {
      "nct_id": "NCT03710876",
      "title": "Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "rAd-IFN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Celecoxib Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ferring Ventures Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2019-01-21",
      "completion_date": "2026-01-16",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03710876"
    },
    {
      "nct_id": "NCT02276820",
      "title": "Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenovirus Infection"
      ],
      "interventions": [
        {
          "name": "Viralym-A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AlloVir",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-07",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2018-07-23",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276820"
    },
    {
      "nct_id": "NCT05271318",
      "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Platinum-refractory Ovarian Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin",
        "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin",
        "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin"
      ],
      "interventions": [
        {
          "name": "TILT-123",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegylated liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TILT Biotherapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2022-05-17",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-04T00:42:53.805Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • New York, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05271318"
    }
  ]
}